trans-lesion bypass synthesis during repair and/or replication, implicating a DNA polymerase or an accessory factor as a basis of the defect in XPV. These results may help to elucidate the repair deficiency in XPV, and they raise the possibility that genetic manipulation via triplex-targeted mutagenesis may be enhanced by modulation of the XPVassociated activity in normal cells.
Oligonucleotides can bind to duplex DNA and form triple helices in a sequence-specific manner (1) (2) (3) (4) . Progress in elucidating the third-strand binding code has led to efforts to exploit nucleic acids as sequence-specific DNA binding reagents for research and possibly therapeutic applications (5) . Oligonucleotide-mediated triplex formation has been shown to prevent transcription factor binding to promoter sites and to block mRNA synthesis in vitro and in vivo (for review, see ref. 5 ). It has also been used in strategies to create unique cleavage sites in DNA in vitro (6) . We have explored the use of triplex-forming oligonucleotides as a mechanism to deliver a tethered mutagen to a selected gene for the site-specific introduction of DNA damage (7) (8) (9) (10) . Psoralen-conjugated oligonucleotides directed to a site in a mutation reporter gene were found to induce targeted mutations in A and simian virus 40 (SV40) DNA in experiments in which the triplex formation was carried out in vitro (7, 8) . In recent work, conditions were determined under which targeted mutagenesis of an SV40 vector could be achieved in vivo in monkey COS cells via intracellular triplex formation using psoralen-linked triplexforming oligonucleotides (10) (19) .
We report the observation of an unusually high frequency of targeted mutations in the XPV cells (an average of 30%), along with a unique spectrum of mutations distinct from that seen in XPA, FA, or normal cell lines. We propose mechanisms to explain these findings, and we suggest that these results not only may help to characterize the DNA repair defect in XPV cells but also may lead to novel strategies to enhance the third-strand-mediated genetic manipulation of mammalian cells.
MATERIALS AND METHODS
Oligonucleotides. Psoralen-linked oligonucleotides were prepared as described (7) (8) (9) (10) . The psoralen is incorporated into the oligonucleotide synthesis as a psoralen phosphoramidite, resulting in an oligonucleotide linked at its 5' end via a two-carbon linker arm to 4'-hydroxymethyl-4,5',8-trimethylpsoralen, pso-AGGAAGGGGG (pso-AG10). Pso-S-S-AG10, containing a disulfide bond in the linker arm connecting the psoralen to the oligonucleotide, was synthesized by incorporation of a thiol modifier (S-S) phosphoramidite (Glen Research, Sterling, VA) into the automated synthesis prior to the addition of the 5' psoralen. To preserve the disulfide linker in the synthesis, modification of the oxidation step was required, as directed by Glen Research.
Vectors. Construction of the shuttle vector plasmid pSP189 has been described (20) . (7) (8) (9) (10) .
In the case of pso-S-S-AG10, the irradiated mixture was further incubated with 50 mM dithiothreitol (DTT) at 55°C for 4 h to release the oligonucleotide by disulfide bond reduction. The detached oligonucleotide was separated from the modified duplex by heating the mixture at 65°C for 5 min and filtration through a Centricon-100 filter (Amicon), yielding pSP189 DNA containing a site-specific psoralen adduct without an associated oligonucleotide.
Successful detachment of the oligonucleotide from the targeted psoralen adduct was monitored by end-labeling pso- (7) (8) (9) (10) .
DNA Sequencing. Sequencing of the supF genes in the mutant colonies was performed as described (10) , using a primer chosen to bind to the 3-lactamase gene just upstream of the supF gene in the vector (20) .
Statistics. The mutation spectra were compared pairwise by using the two-tailed Fischer's exact test. In the case of UVA photoactivation, the mutations were scored as either occurring at position 167 or not at position 167. In the analysis of the visible light-induced spectra, the mutations were scored as at position 166 or not at position 166.
RESULTS
Experimental Strategy. Third-strand-targeted mutagenesis in human cells was studied by using an SV40-based shuttle vector, pSP189 (7, 20) . This vector contains the supF gene, an amber suppressor tyrosine tRNA gene of Escherichia coli, serving as a mutation reporter, along with both the SV40 and pBR327 origins of replication. A 10-base oligonucleotide conjugated to a psoralen derivative at its 5' end, psoralen-AGGAAGGGGG (pso-AG10), was designed to bind as a third strand to bp 167-176 of the supF gene in the purine antiparallel triplex motif (7, 8, 21) and to thereby position the psoralen for intercalation and adduct formation at the 5' ApT 3' site at bp 166 and 167. The third-strand binding site is indicated within the supF sequence in Fig. 1 . 5' GACTTCGAAGGTTCGAAMCCTTCACCA CCA 3' In the XPV cells, the pattern of monoadduct-induced mutations was again distinct (Fig. 2) . Most of the mutations in the normal, XPA, and FA cells were found at bp 166, consistent with the fact that almost all of the visible light-induced adducts are produced at this position. However, in the XPV cells, only 53% of the mutations occurred at bp 166, while 47% occurred at bp 167. Again, the differences between XPV and the other cells were statistically significant (P = 0.02), whereas there were no significant differences between the normal cells and either the XPA or the FA cell lines.
Mutagenesis by Targeted Adducts Detached from the Third Strand. Interpretation of this data is potentially complicated by the fact that the psoralen adduct is presented to the cell in the context of the triple helix. We therefore developed a strategy to direct psoralen adducts to the selected site in the supF gene in such a way that we could subsequently detach and separate the oligonucleotide from the psoralen moiety. An oligonucleotide with the same sequence as pso-AG10 was synthesized to contain a disulfide bond connecting the psoralen to the rest of the oligonucleotide, yielding pso-S-S-AG10 (Fig. 3A) .
The same protocol for targeted adduct formation was used with the pso-S-S-AG10 oligomer. However, after photoactivation of the tethered psoralen the disulfide bond was reduced via DTT treatment to detach the oligonucleotide segment. The detached oligonucleotide was then removed by filtration above the triplex melting temperature. Detachment of the radioactively labeled oligonucleotide was documented by the analysis shown in Fig. 3B . The samples before and after DTT treatment are shown in lanes 2 and 3, respectively. To examine the specificity of the triplex-targeted photoreaction while at the same time verifying the release of the tethered oligonucleotide, the samples were digested with ApaLI. This generates two fragments of 4.4 and 0.6 kb, as shown by the ethidium bromide-stained sample of an ApaLI digest of the pSP189 plasmid DNA (lane 1). The triplex binding site is contained in the 0.6-kb fragment, which is visualized in lane 2 because of the specific attachment of the radiolabeled oligonucleotide to that fragment. Note that there is no detectable labeling of the 4.4-kb band, showing the specificity of the triplex targeting. After the DTT treatment (lane 3), it can be seen that the label has been removed from the 0.6-kb band, demonstrating detachment of the oligonucleotide.
The results of mutagenesis experiments using pso-S-S-AG10 are shown in Table 2 . In comparison to experiments with pso-AG10 (Table 1) , lower induced mutation frequencies were seen in all the cell lines. These lower frequencies likely reflect a lower absolute efficiency of covalent psoralen adduct formation using pso-S-S-AG10 as opposed to pso-AG10, as determined by gel mobility shift Sequence analysis of the pso-S-S-AG10-targeted mutations (Fig. 4) revealed that, in the normal cells, the pattern was the same as in the case of pso-AG10 (Figs. 1 and 2) , with mutations mostly at bp 166 after visible light photoactivation and at bp 167 after UVA. In the XPV cells, the patterns were again different, with mutations occurring at both bp 166 and 167 after either visible light or UVA. With visible light, some mutations in XPV were also seen at bp 165. To explain these mutations, we considered the possibility that the longer linker arm connecting the psoralen to the TFO in pso-S-S-AG10 (Fig. 3A) might allow the tethered psoralen to reach the thymidine in bp 165 and form photoadducts at that site. This was confirmed using a DNA polymerase chain termination assay (data not shown).
DISCUSSION
In this work, we have studied mutagenesis by third-stranddirected psoralen adducts in normal and repair-deficient human cells. We have observed that XPV cells are uniquely defective in the processing of both monoadducts and (16, 17, 22) and almost normal levels of nucleotide excision repair (13, 23) .
Other work has shown diminished DNA synthesis and strand elongation after UVC treatment (13) (14) (15) , as well as inefficient psoralen adduct removal (24) . Recent studies have shown that XPV cells are prone to misincorporation opposite UVCdamaged templates (16, 17) and exhibit altered UVC mutation hotspots (22) .
Consistent with these reports, we have observed an unusual mutation spectrum in XPV. However, because we have used site-directed psoralen adducts, we can make the additional observation that XPV cells are prone to misincorporation not just at the precise position of the adduct but also at adjacent sites.
Mutagenesis by Monoadducts. In the normal, XPA, and FA cells, targeted monoadducts at bp 166 led to primarily T-A -> A-T transversions at that position (Fig. 3 ). Since monoadduct repair should be relatively error-free (and is absent in the XPA cells), these mutations likely arise via translesion bypass synthesis during replication, causing misincorporation of a thymidine opposite the damaged thymidine in the template at bp 166.
In the XPV cells, however, mutations were generated at both bp 166 and 167. Considering the polarity of the strands and the consequent direction of DNA synthesis across the adduct on the thymidine in bp 166, position 167 represents the base pair that comes after the site of damage. Errors at this site may arise from template dislocation and slippage (25) , which could be associated with an abnormality in polymerase proofreading and/or processivity during replication, due either to a polymerase mutation or to a defect in an accessory factor, such as proliferating cell nuclear antigen or replication protein A (26) .
Mutagenesis by Crosslinks. In XPV, the crosslinks resulted in mutations at both bp 166 and 167, while in the other lines, the mutations were mostly at bp 167 (Fig. 2) . We propose that these mutations occur in the process of gap-filling repair synthesis during nucleotide excision repair. In this pathway (27, 28) , a multiprotein complex recognizes and excises the damage via dual incisions in the damaged strand 6 nt 3' and 22 nt 5' from the site of damage (29) . Release of the damaged DNA fragment via helicase activity creates a gap that is filled by repair synthesis (27) .
Complete repair of psoralen crosslinks may involve sequential excision repair acting on both damaged strands. The initial strand repaired is determined in part by the orientation of the psoralen crosslink, with the furan-side lesion preferentially repaired first (30) . In the pso-AG10-directed crosslink, the furan-side adduct is predominantly on the thymidine at position 166, and so repair would, therefore, be biased toward the strand containing this thymidine (9) . After excision of the damaged fragment from that strand, gap-filling repair synthesis would have to bypass the remaining lesion on the other strand at position 167, potentially leading to a mutation at that site. [A more detailed discussion of this model for psoralen adduct repair and mutagenesis in the context of a triple helix has been published elsewhere (31 
